Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.49 |
| ▸ | OGFRL1 | Q5TC84 | 4/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.49 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21311022 | 0.91 | OPRM1 (0.47) | OPRM1OGFRL1OPRD1PDE4BOPRK1 | |
| SCHEMBL21310796 | 0.85 | RORC (0.43) | OPRM1OGFRL1OPRD1PDE4BNAMPT | |
| SCHEMBL21311006 | 0.84 | PDE4B (0.47) | OPRM1OGFRL1OPRD1PDE4BOPRK1 | |
| SCHEMBL9982573 | 0.82 | OPRM1 (0.45) | OPRM1OGFRL1OPRD1HCAR1KDM4E | |
| SCHEMBL9982687 | 0.79 | OPRM1 (0.60) | OPRM1OGFRL1OPRD1OPRK1KDM4E | |
| SCHEMBL26584990 | 0.77 | OPRM1 (0.41) | OPRM1OGFRL1OPRD1PDE4BOPRK1 | |
| SCHEMBL14247494 | 0.77 | USP30 (0.50) | OPRM1OGFRL1OPRD1OPRK1HCAR1 | |
| SCHEMBL21311020 | 0.76 | EGFR (0.44) | PDE4BNAMPTKDM4EMAPTTHRB | |
| SCHEMBL25207474 | 0.75 | PDE4B (0.52) | PDE4BNAMPTKDM4EMAPTTHRB | |
| SCHEMBL15157112 | 0.74 | NAMPT (0.54) | PDE4BNAMPTKDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-11-16 | — | — | US | disclosed |
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377476-A1 | NEW BENZIMIDAZOLE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | OPRM1 875/4885OGFRL1 642/4885OPRD1 1117/4885 |
| US-11174245-B2 | Benzimidazole compounds and derivatives as EGFR inhibitors | EGFR, ERBB2, ERBB3 | OPRM1 967/4885OGFRL1 804/4885OPRD1 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.